Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Therapeutics|February 29, 2016
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of RecurrenceTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.Clinical Therapeutics|February 10, 2016
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's LymphomaNoemi Muszbek, Ananth Kadambi, Tereza Lanitis, et al.Contemporary Clinical Trials Communications|December 5, 2024
Modeling severe uncontrolled asthma: Transitioning away from health statesTereza Lanitis, Asif H Khan, Irina Proskorovsky, et al.Heart Rhythm O2|March 6, 2023
Cost-effectiveness of atrial fibrillation screening in Canadian community practiceJason G Andrade, Anshul Shah, Richard Godin, et al.Applied Health Economics and Health Policy|December 19, 2019
Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USAMustafa Oguz, Tereza Lanitis, Xiaoyan Li, et al.Clinical Therapeutics|October 20, 2015
Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial FibrillationGregory Y H Lip, Tereza Lanitis, Thitima Kongnakorn, et al.Clinical Therapeutics|February 11, 2014
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillationGregory Y H Lip, Thitima Kongnakorn, Hemant Phatak, et al.Journal of Comparative Effectiveness Research|August 23, 2019
Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillationAmber L Martin, Alessandra G Reeves, Samantha E Berger, et al.European Heart Journal|February 12, 2014
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillationPaul Dorian, Thitima Kongnakorn, Hemant Phatak, et al.Pageof 2